Data Sheet (Cat.No.T27837)

TargetMol
YOUR TARGET MOLECULES

Linzagolix

Chemical Properties



CAS No. : 935283-04-8

Formula: C22H15F3N2O7S

Molecular Weight: 508.42

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Targets(IC50)	GNRH Receptor

Solubility Information

Solubility	DMSO: 55 mg/ml (108.18 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9669 mL	9.8344 mL	19.6688 mL
5 mM	0.3934 mL	1.9669 mL	3.9338 mL
10 mM	0.1967 mL	0.9834 mL	1.9669 mL
50 mM	0.0393 mL	0.1967 mL	0.3934 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Womens Health (Lond). 11 (1): 19–28.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481